Rejuvenate Bio
Rejuvenate Bio is a biotechnology company developing gene therapies to treat chronic and age-related diseases. The company’s pipeline includes RJB-0402, a liver-directed FGF21 therapy for metabolic diseases, along with RJB-01, RJB-02, and RJB-03 programs. Rejuvenate Bio initially focused on veterinary applications, developing gene therapy treatments for canine age-related conditions, before translating its platform…
Funding snapshot
About
Rejuvenate Bio is a biotechnology company developing gene therapies to treat chronic and age-related diseases. The company’s pipeline includes RJB-0402, a liver-directed FGF21 therapy for metabolic diseases, along with RJB-01, RJB-02, and RJB-03 programs. Rejuvenate Bio initially focused on veterinary applications, developing gene therapy treatments for canine age-related conditions, before translating its platform to human therapeutics. The company leverages adeno-associated virus (AAV) gene therapy technology to deliver therapeutic genes that address underlying causes of age-related decline, including cardiac, metabolic, and renal diseases. Founded in 2018 and headquartered in San Diego, California, Rejuvenate Bio has raised approximately $34 million in Series A funding. Investors include KdT Ventures, Digitalis Ventures, VCapital, Merck Animal Health, CIRM, Connecticut Innovations, and Companion Fund. The company operates at the intersection of genomics, gene therapy, and metabolic disease treatment, with a team of approximately 16 employees.
Business model
Veterinary HealthTech > Biopharmaceuticals > Diversified,
Cardiac and Vascular Disorders > Drugs > Diversified,
Metabolic Diseases > Drugs > Diversified,
Genomics > Applied Genomics > Clinical Genomics > Therapeutics > Viral Therapeutics > Longevity
Team background
College Wise > Massachusetts Institute of Technology, Harvard University, Duke University, Harvard Business School
Institutional investors
Backed by funds in our directory
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.